DEF 14A

Company

SAB Biotherapeutics, Inc.

Filed

June 2, 2025

Period of Report

July 17, 2025

Accession Number

0000950170-25-080361

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →